Designing the chain beyond collection.
The value of a plasma collection system depends on what happens after the donation: qualification, segregation, handling, storage, traceability, transport, and integration into an appropriate manufacturing pathway.
United Plasma advises public and private stakeholders on the commercial, regulatory, and operational interfaces between collection networks and downstream biologics infrastructure. Our role is strategic and technical advisory; we do not represent ourselves as a licensed plasma fractionator or product manufacturer.
Procurement and logistics
- Plasma supply and demand scenarios, procurement strategies, and contracting considerations.
- Cold-chain workflow concepts, chain of custody, traceability, and transport arrangements.
- Collection network readiness for downstream specifications and partner expectations.
- Risk identification across storage, logistics, documentation, and supplier coordination.
Fractionation and manufacturing pathways
We support feasibility discussions concerning domestic fractionation, contract manufacturing, CDMO or fractionator partnerships, technology transfer, facility planning, and workforce capability development. Projects require detailed technical, commercial, and regulatory assessment before any investment or licensing decision.
Government and national systems
For health ministries and national stakeholders, a sustainable plasma ecosystem must consider donation ethics, healthcare access, public trust, national policy, availability of suitable recovered or source plasma, and routes to plasma-derived therapies.